Pharma-Bio Serv, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.

Symbol
PBSV on OTC
Location
Dorado, PR
Fiscal year end
31 October
Latest financial report
17 Mar 2026

Quick Takeaways

  • PBSV - Pharma-Bio Serv, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q1 2026.
  • Headline metric: Return On Equity -0.68%.

What Changed

  • Return On Equity YoY change: <span class="text-red-600">-82%</span>.
  • Most recent SEC facts end date: 13 Mar 2026.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2026-03-13) highlights Return On Equity -0.7%, Return On Assets -0.5%, and Operating Margin -7.3%.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

39.9/100

Weak Confidence high

Return On Equity

-0.68%

Metric score 0.0/100

Return On Assets

-0.51%

Metric score 0.0/100

Financial Health

Current Ratio
4.03x
Quick Ratio
2.25x
Debt to Equity
0.18x

Strengths

Debt-to-equity and NetIncomeLoss YoY

Watchpoints

Return On Equity, Return On Assets, and Operating Margin

Key metrics snapshot

Return On Equity

-0.68%

YoY: -82%

Industry median: 0.94% (n=58)

View history

Return On Assets

-0.51%

YoY: -82%

Industry median: -5.1% (n=56)

View history

Operating Margin

-7.3%

YoY: -26%

Industry median: 1.4% (n=41)

View history

Current Ratio

4.03x

YoY: -11%

Industry median: 0.84x (n=55)

View history

Quick Ratio

2.25x

YoY: -1.4%

Industry median: 0.6x (n=29)

View history

Debt-to-equity

0.18x

YoY: -20%

Industry median: 0.21x (n=47)

View history

Revenues YoY

-8.1%

YoY:

Industry median: 3.7% (n=43)

View history

NetIncomeLoss YoY

85%

YoY:

Industry median: 3.2% (n=54)

View history

Profitability

Metric Latest value YoY change
Return On Equity -0.68% -82%
Return On Assets -0.51% -82%
Operating Margin -7.2% -26%

Financial Health

Metric Latest value YoY change
Current Ratio 4.03x -11%
Quick Ratio 2.25x -1.4%
Debt-to-equity 0.18x -20%

Growth

Metric Latest value YoY change
Revenues YoY -8.1%
NetIncomeLoss YoY 85%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 22,901,692 -0.13%
Common Stock, Shares, Outstanding 22,902,892 -0.24%
Common Stock, Value, Issued $2,352 0%
Weighted Average Number of Shares Outstanding, Basic 22,905,743 -0.23%
Weighted Average Number of Shares Outstanding, Diluted 22,912,954 -0.21%

Additional Metrics

Metric Latest value YoY change
Cost of Revenue $5,960,432 -13%
Operating Income (Loss) $640,006 +32%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $67,421 +86%
Income Tax Expense (Benefit) $8,718 -16%
Earnings Per Share, Diluted -0.01 +67%
Marketable Securities, Current $4,796,568 -6.5%
Accounts Receivable, after Allowance for Credit Loss, Current $2,654,675 -1%
Assets, Current $13,323,969 -14%
Property, Plant and Equipment, Net $103,674 -35%
Operating Lease, Right-of-Use Asset $0 -100%
Other Assets, Noncurrent $120,783 -46%
Assets $13,548,426 -16%
Liabilities, Current $3,309,695 -3.2%
Liabilities $3,309,695 -19%
Accumulated Other Comprehensive Income (Loss), Net of Tax $280,358 +15%
Retained Earnings (Accumulated Deficit) $8,848,822 -17%
Stockholders' Equity Attributable to Parent $10,238,731 -15%
Liabilities and Equity $13,548,426 -16%
Share-based Payment Arrangement, Noncash Expense $33,017 -24%
Increase (Decrease) in Accounts Receivable $112,892 -139%
Net Cash Provided by (Used in) Operating Activities $175,539 +90%
Net Cash Provided by (Used in) Financing Activities $1,753,042 -1.5%
Net Cash Provided by (Used in) Investing Activities $312,015 -93%
Common Stock, Shares Authorized 50,000,000 0%
Common Stock, Shares, Issued 23,519,672 0%
Common Stock, Par or Stated Value Per Share 0.0001 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,543,505 -273%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5,763,618 -21%
Payments to Acquire Property, Plant, and Equipment $9,055 -94%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $39,664 +92%
Operating Lease, Liability, Current $0 -100%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Authorized 10,000,000 0%
Additional Paid in Capital $1,688,166 +2%
Preferred Stock, Shares Outstanding 0
Preferred Stock, Par or Stated Value Per Share 0.0001 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY